Interleukin-1 (IL-1) Blockade in Acute Myocardial Infarction (VCU-ART3)

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

99

Participants

Timeline

Start Date

July 1, 2014

Primary Completion Date

December 23, 2018

Study Completion Date

December 23, 2018

Conditions
Acute Myocardial Infarction
Interventions
DRUG

Anakinra 100 mg

Anakinra 100 mg starting immediately and then every 24 hours

DRUG

Anakinra 100 mg

Anakinra 100 mg starting 12 hours after first dose and then every 24 hours (so that Anakinra is given every 12 hours)

DRUG

Placebo

Placebo 0.67 ml injections twice daily

Trial Locations (2)

20010

Washington Hospital Center, Washington D.C.

23298

Virginia Commonwealth University, Richmond

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Virginia Commonwealth University

OTHER

NCT01950299 - Interleukin-1 (IL-1) Blockade in Acute Myocardial Infarction (VCU-ART3) | Biotech Hunter | Biotech Hunter